**HPTN 083-01**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
- About 50 adolescents assigned male at birth, including cisgender men who have sex with men, transgender women (TGW) and gender non-conforming people

**Locations**
- United States: Boston, MA; Chicago, IL; Memphis, TN

**Study Design**
- Single arm open label study evaluating the safety, tolerability and acceptability of CAB LA

**Study Steps**
- **STEP 1**
  - A daily oral pill for 5 weeks

- **STEP 2**
  - An injection every 8 weeks for 29 weeks

- **STEP 3**
  - A daily oral pill for 48 weeks

**HPTN 084-01**

**Active Products**
- Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
- About 50 cisgender adolescents assigned female at birth

**Locations**
- Africa: South Africa, Uganda, Zimbabwe

**Study Design**
- Single arm open label study evaluating the safety, tolerability and acceptability of CAB LA

**Study Steps**
- **STEP 1**
  - A daily oral pill for 5 weeks

- **STEP 2**
  - An injection every 8 weeks for 29 weeks

- **STEP 3**
  - A daily oral pill for 48 weeks